ABSTRACT
Fig. 16.6 Effects of placebo and zoledronate on biochemical markers of bone resorption, (a) Ratio of NTX to creatinine, (b) serum concentration of C-telopeptide of type I collagen (CTX), following administration of placebo or the following regimes of IV zoledronate: 4 x 0.25 mg, 4 x 0.5 mg, 4 x 1 mg, 2 x 2 mg, 1 X 4 mg. All active treatment groups were associated with significantly reduced resorption markers as compared to the placebo group, from 1 month onwards. Source: Reid et al. (2002).
